Clinical Research Directory

Inclusion Criteria: * Willing to sign the written informed consent form for male and female participants aged 18 and above. * At the time of enrollment, diagnosed with HIV infection for a minimum of 12 months. * Under oral antiretroviral treatment (ART), which can be irregular or interrupted, with the most recent viral load ≥ 200 copies/mL. * Body weight ≥ 35Kg. * Willing to maintain contact with the research team throughout the study (provide accurate and reachable phone numbers, social accounts like Line, or reliable contact information of family or friends). * Willing to receive gluteal (buttocks) drug injections. * Willing to transition back to oral medication or follow the recommended treatment prescription according to the then-current national treatment guidelines after discontinuation of long-acting injectable drugs. Exclusion Criteria: * For those currently undergoing oral antiretroviral therapy, who have started or restarted oral ART for less than six consecutive months before screening. * Previously undergone HIV drug resistance testing and known to have resistance mutations to either cabotegravir or rilpivirine. * Unable to commit to maintaining contact with the research team throughout the study. * Individuals who cannot receive treatment for hepatitis B during the period of transitioning to long-acting injections, if they are hepatitis B carriers. * Individuals with buttock fillers. * Women who are planning to become pregnant, pregnant, or currently breastfeeding.